These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 18991661)

  • 41. Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches.
    Lang AE
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):210-20. PubMed ID: 6143611
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel pharmacological strategies for motor complications in Parkinson's disease.
    Konitsiotis S
    Expert Opin Investig Drugs; 2005 Apr; 14(4):377-92. PubMed ID: 15882115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can adenosine A
    Kanda T; Jenner P
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Development of disease-modifying drugs for Parkinson's disease. Is it a tough road?].
    Nagai M
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):223-227. PubMed ID: 36990797
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New medical and surgical treatments for Parkinson's disease.
    Klockgether T; Löschmann PA; Wüllner U
    Curr Opin Neurol; 1994 Aug; 7(4):346-52. PubMed ID: 7952244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological treatment of Parkinson's disease.
    Münchau A; Bhatia KP
    Postgrad Med J; 2000 Oct; 76(900):602-10. PubMed ID: 11009573
    [No Abstract]   [Full Text] [Related]  

  • 48. Safinamide for the treatment of Parkinson's disease.
    Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T
    Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease.
    Gerlach M; Double K; Reichmann H; Riederer P
    J Neural Transm Suppl; 2003; (65):167-83. PubMed ID: 12946055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Future drug targets for Parkinson's disease].
    Hirsch EC
    Bull Acad Natl Med; 2012 Oct; 196(7):1369-77; discussion 1377-9. PubMed ID: 23815021
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New drugs for the treatment of Parkinson's disease.
    LeWitt PA
    Pharmacotherapy; 2000 Jan; 20(1 Pt 2):26S-32S. PubMed ID: 10641989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.
    Laurencin C; Danaila T; Broussolle E; Thobois S
    Rev Neurol (Paris); 2016; 172(8-9):512-523. PubMed ID: 27476416
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
    Maranis S; Tsouli S; Konitsiotis S
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.
    Kim HJ; Jeon BS; Jenner P
    Int Rev Neurobiol; 2017; 132():295-343. PubMed ID: 28554412
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Dopamine agonists--pharmacological similarities and differences].
    Honczarenko K; Białecka M
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S1-5. PubMed ID: 17941451
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.